Achromatopsia
This is a rare disorder which affects around 1 person in 33,000. There are complete and incomplete forms of achromatopsia. Persons with complete achromatopsia have no cone vision and so rely on their “rod vision.” Rods are located mostly at the periphery of the retina. Therefore patients are not able to adapt normally to higher levels of illumination. Rods do not provide colour vision or good detail vision. Therefore, persons with achromatopsia are either totally colour-blind or almost totally colour-blind, and they have poor visual acuity. The type of vision loss is varies considerably. There are complete rod monochromats, incomplete rod monochromats, and blue cone monochromats. Complete rod monochromats have the most severely impaired vision of all achromats. Blue cone monochromacy is much rarer than rod monochromacy and has entirely different inheritance factors.
Sometimes a patient with rod monochromacy may be diagnosed as having cone dystrophy Congenital achromatopsia is not progressive, and it does not lead to blindness. Some doctors refer to it as “stationary cone dystrophy.”
Nystagmus (involuntary movement of the eyes) is a symptom of achromatopsia, one that is especially noticeable during infancy and childhood, but having this symptom is not the same as having the medical eye condition which is known as “congenital nystagmus.”Patients are very uncomfortable in full sunlight outdoors or in very bright indoor spaces, so almost all achromats use very dark tinted lenses.
Choroideremia
Choroideremia is a retinal degeneration that begins with reduction of night vision and gradually progresses to blindness by middle age. The appearance of the fundus in sufferers is recognizable by the characteristic pale colour caused by the loss of the outer retina, retinal-pigmented epithelium, and choroidal vessels, leading to exposure of the underlying sclera. Choroideremia is inherited in an X linked recessive way. The CHM gene encodes for the Rab escort protein 1 (REP1). Research towards establishing a clinical trial is under way.
Gyrate Atrophy
This rare condition causes atrophy of the choroid and the retina. Affected patients usually develop night blindness during the first decade of life and experience progressive loss of visual field and visual acuity later in the disease course. The vision loss is progressive and as yet untreatable. It is inherited in an autosomal recessive pattern.
The gene mutation is found on chromosome 10 which encodes for an enzyme called ornithine ketoacid aminotransferase (OAT). Different mutations in OAT cause differences in the severity of symptoms of the disease. It is known that reduction of the amino acid arginine in the diet has a beneficial effect on most patients, but the diet is very difficult to maintain and must be monitored by pediatricians with experience in metabolic diseases. Vitamin B6 treatment lowers the plasma ornithine levels in a small percentage of gyrate atrophy patients. Whether such a reduction improves the long-term visual outcome is unknown, but, unlike arginine restriction, vitamin supplementation is relatively easy to administer. Long-term vitamin therapy should be considered only for patients whose ornithine levels can be shown to drop in response to treatment.
Leber Congenital Amaurosis
LCA is an inherited retinal degenerative disease characterized by severe loss of vision at birth. A variety of other eye-related abnormalities including roving eye movements, deep-set eyes, and sensitivity to bright light also occur with this disease. Some patients with LCA also experience central nervous system abnormalities.
Eye examinations of infants with LCA reveal normal appearing retinas. However, electroretinography (ERG) tests, which measure visual function, detect little if any activity in the retina. A low level of retinal activity, measured by ERG, indicates very little visual function. ERG tests are key to establishing a diagnosis of LCA. By early adolescence, various changes in the retinas of patients with LCA become readily apparent. Blood vessels often become narrow and constricted. A variety of pigmentary changes can also occur in the retinal pigment epithelium (RPE), the supportive tissue underlying the retina. Sometimes, pigmentary changes are similar to another retinal degenerative disease known as retinitis pigmentosa. Although the appearance of the retina undergoes marked changes with age, vision usually remains fairly stable through young adult life. Some patients are also extremely sensitive to light (photophobia). Patients with remaining vision are often extremely farsighted.
LCA is genetically passed through families by the autosomal recessive pattern of inheritance. In this type of inheritance, both parents are carriers of a single copy of a gene mutation. To date more than 15 genes have been associated with LCA. Gene replacement for the RPE65 form has been in gene replacement clinical trials for many years and will soon become commercially available. See also the information on genetics and research on this website. Call Retina South Africa to find out about genetic testing.
Retinoschisis
This is a genetic disorder that causes splitting through the layers of the retina, the light-sensitive neural tissue in the back of the eye. The disorder is characterized by a slow, progressive loss of parts of the field of vision corresponding to the areas of the retina that have become split. It may be associated with the development of saclike blisters (cysts) in the retina. Patients will have a reduction in visual acuity and there may also be a loss of peripheral vision. Very few people become totally blind but it may result in very poor vision in later years. Vision loss usually starts by early grade school age and slowly worsens over the next several decades as cells in the retina lose function and die. The gene mutations are carried on the X chromosome and thus inherited from mother to child. Typically only males develop symptoms. The causative gene is Retinoschisin 1 (RS1) which codes for the retinoschisin protein, which normally works like double-sided tape, providing lateral adhesion that holds retinal cells together. RS1 gene mutations alter the protein and thereby interfere with the ability of cells to maintain proper structure of the retina. The first- ever human gene therapy trial for XLRS is in progress. Retina South Africa is working with the University of Cape Town to bring promising clinical trials and therapies to South Africa.
Information on other rare retinal conditions is available from Retina South Africa :
- Fundus albipunctatis
- Familial exudative vitreoretinopathy
- Kearns-Sayre syndrome
- Lawrence Moon and Bardet-Biedl syndrome
- Dominant drusen
- Macular pattern dystrophy
- Sorsby’s Fundus Dystrophy
- Refsum disease
- Atypical RP [ punctata albescens, rp+ ex. Vas.etc]
- Pseudoxanthoma elasticum
- Stationary nightblindness